OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Degraders upgraded: the rise of PROTACs in hematological malignancies
Joshua Casan, John F. Seymour
Blood (2024) Vol. 143, Iss. 13, pp. 1218-1230
Closed Access | Times Cited: 15
Joshua Casan, John F. Seymour
Blood (2024) Vol. 143, Iss. 13, pp. 1218-1230
Closed Access | Times Cited: 15
Showing 15 citing articles:
Targeted protein degradation: advances in drug discovery and clinical practice
Guangcai Zhong, Xiaoyu Chang, Weilin Xie, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 13
Guangcai Zhong, Xiaoyu Chang, Weilin Xie, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 13
The value of protein allostery in rational anticancer drug design: an update
Ruth Nussinov, Hyunbum Jang
Expert Opinion on Drug Discovery (2024) Vol. 19, Iss. 9, pp. 1071-1085
Open Access | Times Cited: 7
Ruth Nussinov, Hyunbum Jang
Expert Opinion on Drug Discovery (2024) Vol. 19, Iss. 9, pp. 1071-1085
Open Access | Times Cited: 7
DrugMAP 2.0: molecular atlas and pharma-information of all drugs
Fengcheng Li, Minjie Mou, LI Xiao-yi, et al.
Nucleic Acids Research (2024) Vol. 53, Iss. D1, pp. D1372-D1382
Open Access | Times Cited: 6
Fengcheng Li, Minjie Mou, LI Xiao-yi, et al.
Nucleic Acids Research (2024) Vol. 53, Iss. D1, pp. D1372-D1382
Open Access | Times Cited: 6
The emerging role of targeted protein degradation to treat and study cancer
Maximillian H. Brodermann, Elizabeth Henderson, Rob S. Sellar
The Journal of Pathology (2024) Vol. 263, Iss. 4-5, pp. 403-417
Open Access | Times Cited: 5
Maximillian H. Brodermann, Elizabeth Henderson, Rob S. Sellar
The Journal of Pathology (2024) Vol. 263, Iss. 4-5, pp. 403-417
Open Access | Times Cited: 5
Simplified Maxwell-Boltzmann-Hansch Function (SMBH function) and its Application in PROTAC
Xuan Cao, Kaiyue Wu, Junfeng Qu, et al.
(2025)
Closed Access
Xuan Cao, Kaiyue Wu, Junfeng Qu, et al.
(2025)
Closed Access
The BCL2 family: from apoptosis mechanisms to new advances in targeted therapy
Meike Vogler, Yannick Braun, Victoria M. Smith, et al.
Signal Transduction and Targeted Therapy (2025) Vol. 10, Iss. 1
Open Access
Meike Vogler, Yannick Braun, Victoria M. Smith, et al.
Signal Transduction and Targeted Therapy (2025) Vol. 10, Iss. 1
Open Access
Targeted protein degradation in hematologic malignancies: latest updates from the 2023 ASH annual meeting
Guangcai Zhong, Ran Kong, Shi Feng, et al.
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 3
Guangcai Zhong, Ran Kong, Shi Feng, et al.
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 3
Defeating MYC with drug combinations or dual-targeting drugs
Philip E. Thompson, Jake Shortt
Trends in Pharmacological Sciences (2024) Vol. 45, Iss. 6, pp. 490-502
Closed Access | Times Cited: 3
Philip E. Thompson, Jake Shortt
Trends in Pharmacological Sciences (2024) Vol. 45, Iss. 6, pp. 490-502
Closed Access | Times Cited: 3
Selective degradation of mutant FMS-like tyrosine kinase-3 requires BIM-dependent depletion of heat shock proteins
Melisa Halilovic, Mohamed Abdelsalam, Joanna Zabkiewicz, et al.
Leukemia (2024) Vol. 38, Iss. 12, pp. 2561-2572
Open Access | Times Cited: 3
Melisa Halilovic, Mohamed Abdelsalam, Joanna Zabkiewicz, et al.
Leukemia (2024) Vol. 38, Iss. 12, pp. 2561-2572
Open Access | Times Cited: 3
Selection of DNA-encoded Chemical Libraries for Compounds that can Induce Protein Ubiquitination
Cen Huang, Xing‐Yuan Liu, Xinyuan Wu, et al.
(2024)
Open Access | Times Cited: 1
Cen Huang, Xing‐Yuan Liu, Xinyuan Wu, et al.
(2024)
Open Access | Times Cited: 1
Targeted protein degradation in hematologic malignancies: clinical progression towards novel therapeutics
Yupiao Feng, Xinting Hu, Xin Wang
Biomarker Research (2024) Vol. 12, Iss. 1
Open Access | Times Cited: 1
Yupiao Feng, Xinting Hu, Xin Wang
Biomarker Research (2024) Vol. 12, Iss. 1
Open Access | Times Cited: 1
Tumor Biology Hides Novel Therapeutic Approaches to Diffuse Large B-Cell Lymphoma: A Narrative Review
Romana Masnikosa, Zorica Cvetković, David Pirić
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 21, pp. 11384-11384
Open Access | Times Cited: 1
Romana Masnikosa, Zorica Cvetković, David Pirić
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 21, pp. 11384-11384
Open Access | Times Cited: 1
BCL-2 and BTK inhibitors for chronic lymphocytic leukemia: current treatments and overcoming resistance
Tadeusz Robak, Magdalena Witkowska, Anna Wolska, et al.
Expert Review of Hematology (2024)
Closed Access
Tadeusz Robak, Magdalena Witkowska, Anna Wolska, et al.
Expert Review of Hematology (2024)
Closed Access
Toosendanin: upgrade of an old agent in cancer treatment
Shuwei Li, Qingyi Xiong, Yilei Shen, et al.
Chinese Journal of Natural Medicines (2024) Vol. 22, Iss. 10, pp. 887-899
Closed Access
Shuwei Li, Qingyi Xiong, Yilei Shen, et al.
Chinese Journal of Natural Medicines (2024) Vol. 22, Iss. 10, pp. 887-899
Closed Access
Targeted KRASG12Vdegradation elicits efficient and durable lung adenocarcinoma regressionin vivo
Alberto J. M. Martín, Inmaculada García-Peréz, Sonia San José, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Alberto J. M. Martín, Inmaculada García-Peréz, Sonia San José, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
